Every material Form 8-K Chemomab Therapeutics Ltd. has filed with the SEC since May 11, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Chemomab Therapeutics appointed Sigal Fattal, its former VP of Finance, as Chief Financial Officer on June 1, 2023, and the Board approved her compensation on June 14, 2023. The package includes a $260,000 base salary, a bonus potential of 45% of base salary tied to objectives yet to be set, and options on 102,860 ADSs at $1.70 that vest over four years.
Appointed Sigal Fattal as Chief Financial Officer on June 1, 2023; she previously served as VP of Finance
Annual base salary of $260,000, plus a bonus potential of 45% of base salary
Options to buy 102,860 American Depositary Shares at $1.70, vesting over four years, with acceleration on a change in control
Chemomab Therapeutics replaced CEO Dale Pfost and CFO Donald Marvin effective June 1, 2023, reappointing co-founder Adi Mor as CEO and Sigal Fattal as CFO, and named Nissim Darvish Chairman. The company also said it is implementing further cost-reduction measures to extend its cash runway to the end of 2024 and is suspending initiation of a Phase 2 systemic sclerosis trial to preserve capital.
Adi Mor appointed CEO effective June 1, 2023; her compensation will be set later and subject to shareholder approval
Sigal Fattal appointed CFO, replacing Donald Marvin, effective June 1, 2023
Cash runway expected to extend from mid-year 2024 to end of 2024, after the Phase 2 PSC topline data readout expected in the latter part of 2024
Former CEO Dale Pfost will receive 12 months of base salary in cash, accelerated stock option vesting and 12 months of COBRA premiums, subject to a separation agreement
Chemomab Therapeutics reported a first-quarter 2023 net loss of $8.8 million, up from $5.1 million a year earlier, driven mainly by higher research and development spending. Cash, cash equivalents and short-term deposits fell to $32.8 million at March 31, 2023, from $39.9 million at December 31, 2022, and the company said its estimated cash runway now extends through the first half of 2024.
Net loss was $8.8 million, or about $0.04 per share, versus $5.1 million, or about $0.02 per share, in the first quarter of 2022.
R&D expenses were $6.9 million versus $2.7 million a year earlier, primarily due to increased clinical and preclinical activities.
Cash, cash equivalents and short-term bank deposits were $32.8 million at March 31, 2023, compared with $39.9 million at December 31, 2022.
Estimated cash runway was extended through the first half of 2024; the CM-101 Phase 2 PSC trial top-line data are expected in the second half of 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Chemomab Therapeutics Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →